Loading clinical trials...
Loading clinical trials...
To assess the prevalence of Metabolic Syndrome in Spanish population with Bipolar I or II Disorder. To analyse the clinical progress disease in patients with Bipolar I or II Disorder for 12 months using the assessment of the symptoms disease and the progress of metabolic and cardiovascular risk. To analyse the health status, quality of life and functioning/disability of patients.
Consecutive patient sampling. In any investigational site, five consecutive patients with diagnosis of Bipolar Disorder will be enrolled in the study
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
May 1, 2007
Primary Completion Date
February 1, 2009
Completion Date
February 1, 2009
Last Updated
February 21, 2021
553
ACTUAL participants
non-interventional
OTHER
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
NCT04480918
NCT07140913
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions